Home/News Feed/Global biotech market hits $2.02T in 2026, set to triple by 2035 amid record deals and strong Q3 growth. The global biotechnology market reached a valuation of USD 2.02 trillion in 2026 and is projected to grow to USD 6.34 trillion by 2035, driven by a 13.61% CAGR. Leading companies like Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong third-quarter results, with revenues rising between 8% and 36%. The year 2026 saw unprecedented dealmaking, including Gilead's $12.7 billion in acquisitions and major purchases by Sun Pharma and GSK, as firms seek to replenish pipelines ahead of patent expiries. Key growth areas include immunology, oncology, gene editing, and mRNA vaccines, while challenges remain in biosimilar competition and high R&D costs. The market outlook remains robust with expanding collaborations and rising R&D investments.
Amgen leads with a market cap of $250.07 billion on Pluang as of Nov 17, 2026, 22:13 WIB, despite a slight 0.75% dip in its share price. This aligns with the strong 2026 results reported by major biotech firms like Amgen and Gilead, which is trading at $169.41 with a 1.09% gain. The sector's robust growth outlook is reflected in active trading volumes, such as Moderna's 7,000,987 shares traded, even as its price fell 3.89% on the day.